ABT 700

Drug Profile

ABT 700

Alternative Names: ABT-700; h224G11; Mab-224G11; Mab-h224G11

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Pierre Fabre
  • Developer AbbVie
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Apr 2017 AbbVie completes a phase I trial for Solid tumours in USA, South Korea and Taiwan (NCT01472016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top